Aspire BioPharma, Inc. (ASBP)vsTesla Inc (TSLA)
ASBP
Aspire BioPharma, Inc.
$8.88
+5.21%
CONSUMER CYCLICAL · Cap: $11.80M
TSLA
Tesla Inc
$407.46
-0.80%
CONSUMER CYCLICAL · Cap: $1.40T
Smart Verdict
WallStSmart Research — data-driven comparison
Tesla Inc generates 106101684% more annual revenue ($103.62B vs $97,660). TSLA leads profitability with a 3.7% profit margin vs 0.0%. TSLA earns a higher WallStSmart Score of 31/100 (F).
ASBP
Avoid22
out of 100
Grade: F
TSLA
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ASBP.
Margin of Safety
-42.3%
Fair Value
$261.56
Current Price
$407.46
$145.90 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Conservative balance sheet, low leverage
Revenue surging 25.5% year-over-year
Generating 1.5B in free cash flow
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 18.5x book value
ROE of 3.6% — below average capital efficiency
3.7% margin — thin
Operating margin of 1.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : ASBP
The strongest argument for ASBP centers on Price/Book.
Bull Case : TSLA
The strongest argument for TSLA centers on Market Cap, Debt/Equity, Revenue Growth. Revenue growth of 25.5% demonstrates continued momentum.
Bear Case : ASBP
The primary concerns for ASBP are Revenue Growth, EPS Growth, Market Cap.
Bear Case : TSLA
The primary concerns for TSLA are Price/Book, Return on Equity, Profit Margin. A P/E of 328.4x leaves little room for execution misses. Thin 3.7% margins leave little buffer for downturns.
Key Dynamics to Monitor
ASBP profiles as a value stock while TSLA is a growth play — different risk/reward profiles.
TSLA carries more volatility with a beta of 1.92 — expect wider price swings.
TSLA is growing revenue faster at 25.5% — sustainability is the question.
TSLA generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
TSLA scores higher overall (31/100 vs 22/100) and 25.5% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aspire BioPharma, Inc.
CONSUMER CYCLICAL · AUTO PARTS · USA
Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company is headquartered in Humacao, Puerto Rico.
Visit Website →Tesla Inc
CONSUMER CYCLICAL · AUTO MANUFACTURERS · USA
Tesla, Inc. is an American electric vehicle and clean energy company based in Palo Alto, California. Tesla's current products include electric cars, battery energy storage from home to grid-scale, solar panels and solar roof tiles, as well as other related products and services. In 2020, Tesla had the highest sales in the plug-in and battery electric passenger car segments, capturing 16% of the plug-in market (which includes plug-in hybrids) and 23% of the battery-electric (purely electric) market. Through its subsidiary Tesla Energy, the company develops and is a major installer of solar photovoltaic energy generation systems in the United States. Tesla Energy is also one of the largest global suppliers of battery energy storage systems, with 3 GWh of battery storage supplied in 2020.
Visit Website →Compare with Other AUTO PARTS Stocks
Want to dig deeper into these stocks?